Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSanofi Share News (SAN.PA)

Share Price Information for Sanofi (SAN.PA)

Euronext Paris
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 90.79
Bid: 93.35
Ask: 93.36
Change: 0.00 (0.00%)
Spread: 0.01 (0.011%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 90.79
SAN.PA Live PriceLast checked at -
  • This share is an international stock.

Watchlists are a member only feature

Login to your account

STOXX 600 closes at record high on earnings, rate cut optimism

Fri, 10th May 2024 17:21

Rio Tinto considered bid for BHP-target Anglo American -report

*

Green energy production in Italy boosts Enel's Q1 results

*

Medical gear maker Getinge plummets after FDA's safety warning

*

Italy industry output posts unexpected fall in March

May 10 (Reuters) - Europe's main stock index closed at a record high on Friday, on track for its biggest weekly gain since late January, as risk appetite was bolstered by growing bets on interest rate cuts in the region and a strong earnings season.

The pan-European STOXX 600 ended 0.7% higher, with indexes in major economies Germany and France finishing at record highs.

European shares have resumed their record-breaking rally, with the STOXX 600 notching a 3% weekly gain, after investors took a breather in April.

The euphoria around artificial intelligence and monetary policy easing, among others, had sparked bumper gains in the region's stocks since late 2023.

Highlighting Europe's divergence from the U.S. Federal Reserve and boosting equities, the Bank of England hinted at summer rate cuts and Sweden's Riksbank delivered its first cut since 2016 earlier this week.

Minutes from the ECB's April policy meeting showed that policymakers favoured kicking off the monetary policy easing cycle in June, while remaining confident that inflation is on track to fall back to 2% next year.

"Looking beyond June, the path for the bank is anything but clear. The risk of reflation has clearly increased," said Carsten Brzeski, global head of macro at ING Research.

"Any signs of reflation and also stronger economic activity would limit the ECB's room for manoeuvre."

Leading sectoral gains, utilities advanced 1.4%, with Italy's Enel climbing 3.8% following a higher first-quarter core profit. Portugal's largest utility firm EDP climbed 3.9% after a bigger-than-expected jump in first-quarter net profit.

Retailers added 1.5%, with Zalando rising 3.3% after Berenberg upgraded the German online retailer to "buy" from "hold".

Among M&A developments, shares of BBVA and Sabadell were up 1.3% and 0.5%, respectively, as investors assessed the developments around the first hostile banking takeover bid in Spain since the 1980s.

Anglo American advanced 1.4% after a report said mining giant Rio Tinto had considered an offer for the British miner.

Sanofi rose 1.3% after Novavax struck a licensing deal of up to $1.2 billion with French drugmaker for its COVID-19 vaccine in exchange for a stake that valued the U.S. biotech firm at double its current market capitalisation.

On the flip side, Getinge slumped 8.8% to the bottom of the STOXX after the U.S. FDA issued a warning on the safety of two of the Swedish medical equipment maker's heart devices.

Symrise shed 1.4% after Berenberg downgraded the German flavour and fragrance maker to "hold" from "buy".

On the data front, Italian industrial output was much weaker than expected in March, extending the pain for the country's struggling manufacturing sector. (Reporting by Ankika Biswas and Johann M Cherian in Bengaluru; Editing by Rashmi Aich, Eileen Soreng and Jane Merriman)

More News
5 Jul 2023 12:04

China extends squeezed-out foreign pharmaceuticals firms an olive branch

BEIJING, July 5 (Reuters) - China's Commerce Minister told foreign pharmaceuticals firms they can expect "more development opportunities" during a roundtable on Wednesday, his ministry said, as drugmakers bemoan government procurement policies pricing them out of the market.

Read more
30 Jun 2023 22:38

First trial over Zantac cancer claims set for November

June 30 (Reuters) - The first U.S. trial over claims that discontinued heartburn drug Zantac causes cancer is now expected to take place in California state court on Nov. 13, a lawyer for plaintiffs in the litigation said Friday.

Read more
29 Jun 2023 06:30

Sanofi says it's back to the drawing board on mRNA flu vaccines

June 29 (Reuters) - Sanofi said that trials show the currently available mRNA technology behind the most successful COVID-19 shots will not be effective against influenza and it is already working on a next generation of shots.

Read more
23 Jun 2023 20:24

GSK soothes investors by settling first Zantac cancer lawsuit due for US trial

GSK shares best performer on London's stock market

*

Read more
22 Jun 2023 14:02

Novo Nordisk says EMA raised safety signal on drugs including semaglutide

Signal included drugs from Eli Lilly, AstraZeneca, Sanofi

*

Read more
22 Jun 2023 08:54

Novo Nordisk shares slip on EMA drug safety signal

COPENHAGEN, June 22 (Reuters) - Novo Nordisk said on Thursday the European Union's drug watchdog had last month raised a thyroid cancer safety signal for several of its drugs including semaglutide, the active ingredient in its popular diabetes and obesity drugs, Ozempic and Wegovy.

Read more
20 Jun 2023 17:44

China-exposed miners, luxury shares drag STOXX 600 down; Lanxess plunges

China-exposed miners and luxury stocks weigh

*

Read more
31 May 2023 23:35

US FDA approves Pfizer's RSV vaccine

May 31 (Reuters) - The U.S. Food and Drug Administration on Wednesday approved Pfizer Inc's respiratory syncytial virus (RSV) vaccine for older adults, making it the second shot against the common respiratory disease that can be fatal for seniors.

Read more
27 Apr 2023 12:36

AstraZeneca increases bets on China as COVID vaccine sales fade

AstraZeneca already biggest drugmaker in China

*

Read more
27 Mar 2023 23:51

Amgen-Sanofi patent case divides makers of antibody drugs

March 27 (Reuters) - Amgen Inc's battle with Sanofi and Regeneron at the U.S. Supreme Court over its cholesterol drug Repatha on Monday has some drugmakers hoping a ruling will reshape U.S. patent law and competition among companies that make antibody medicines.

Read more
24 Mar 2023 15:25

GSK loses bid to keep experts out of upcoming Zantac trial

March 24 (Reuters) - A California judge on Thursday denied GSK Plc's bid to keep expert testimony linking its discontinued heartburn drug Zantac to cancer out of an upcoming trial, a setback for the British drugmaker facing lawsuits over the medicine in courts across the United States.

Read more
23 Mar 2023 17:09

Banks drag European shares down as c.banks join Fed in raising rates

Banks down 2.4%, rate-sensitive tech up 2.2%

*

Read more
20 Mar 2023 06:00

Vaccine makers prep bird flu shot for humans 'just in case'; rich nations lock in supplies

LONDON, March 20 (Reuters) - Some of the world's leading makers of flu vaccines say they could make hundreds of millions of bird flu shots for humans within months if a new strain of avian influenza ever jumps across the species divide.

Read more
13 Mar 2023 17:13

European stocks log steepest one-day fall this year as banks extend slide

European banks log worst two-day selloff in a year

*

Read more
24 Feb 2023 15:10

First Zantac cancer risk trial in Calif. postponed five months

Feb 23 (Reuters) - The first scheduled trial over claims that GSK Plc's heartburn drug Zantac caused cancer, which had been set to begin Monday, has been postponed by five months.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.